Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARDX
Strong SellSinkerArdelyx, Inc. · Healthcare · United States · $984M · Avg Vol: $17M/d
COMPANY DESCRIPTION
Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class targeted therapies for gastrointestinal and cardiorenal diseases. The company's competitive moat is anchored by its proprietary drug discovery platform, which has yielded unique mechanism-of-action treatments such as Ibsrela for IBS-C and Xphozah for hyperphosphatemia. By addressing significant unmet medical needs with patented, novel small molecules, Ardelyx is establishing a strong foothold in specialized therapeutic markets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 52.2M | 124.5M | 333.6M | 407.3M | 98.4% | 450.9M | 488.8M | 623.9M | 23.8% |
| EPS | -0.42 | -0.30 | -0.17 | -0.26 | — | -0.23 | -0.20 | 0.25 | — |
| Shares | 198.6M | 232.5M | 238.0M | 244.4M | +23.1% | 258.2M | — | — | — |
| Debt | 36.5M | 56.0M | 153.4M | 208.0M | 78.7% | 282.5M | — | — | — |
| Equity | 98.3M | 166.8M | 173.3M | 166.9M | 19.3% | — | — | — | — |
| Op CF | -70.0M | -89.7M | -44.8M | -42.5M | — | -17.3M | — | — | — |
| Inv CF | 18.4M | -131.2M | -18.3M | -9.0M | — | — | — | — | — |
| Fin CF | 75.3M | 146.3M | 106.6M | 54.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARDX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARDX | Ardelyx, Inc.(you) | $984M | 14 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $884M | 14 | Strong Sell |
| GERN | Geron Corporation | $970M | 16 | Strong Sell |
| SVRA | Savara Inc. | $1.1B | 12 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 11 | Strong Sell |
| PHAT | Phathom Pharmaceuticals, Inc. | $743M | 14 | Strong Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 19 | Strong Sell |
| STTK | Shattuck Labs, Inc. | $707M | 16 | Strong Sell |
| NVAX | Novavax, Inc. | $1.5B | 14 | Strong Sell |
| ATTO | Attovia Therapeutics, Inc. | $891M | 7 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%